Neuraminidase-Inhibiting Antibodies Induced by Either MF59- or AS03-Adjuvanted A(H7N9) Candidate Vaccine Virus
| Adjuvant . | Serum Pairsa . | N9 Antigenb . | Pre-GMT (95% CI) . | Post-GMT (95% CI) . | Seroconversion, No. (%)c . |
|---|---|---|---|---|---|
| MF59 | n = 30 | H6N9 virus (AH1) | 6.5 (5.3–8.1) | 68.9 (49.6–95.7) | 25/30 (83.3) |
| H6N9 virus (GD17S) | 10.7 (7.2–15.9) | 228.9 (169.4–309.3) | 28/30 (93.33) | ||
| AS03 | n = 30 | H6N9 virus (AH1) | 9.0 (6.3–12.8) | 94.0 (64.1–138.1) | 25/30 (83.3) |
| H6N9 virus (GD17S) | 21.1 (11.9–37.9) | 254.0 (179.3–360.0) | 27 (90.00) |
| Adjuvant . | Serum Pairsa . | N9 Antigenb . | Pre-GMT (95% CI) . | Post-GMT (95% CI) . | Seroconversion, No. (%)c . |
|---|---|---|---|---|---|
| MF59 | n = 30 | H6N9 virus (AH1) | 6.5 (5.3–8.1) | 68.9 (49.6–95.7) | 25/30 (83.3) |
| H6N9 virus (GD17S) | 10.7 (7.2–15.9) | 228.9 (169.4–309.3) | 28/30 (93.33) | ||
| AS03 | n = 30 | H6N9 virus (AH1) | 9.0 (6.3–12.8) | 94.0 (64.1–138.1) | 25/30 (83.3) |
| H6N9 virus (GD17S) | 21.1 (11.9–37.9) | 254.0 (179.3–360.0) | 27 (90.00) |
Abbreviations: CI, confidence interval; GMT, geometric mean titer.
pre- day 0 of the vaccination. post- day 42–52 after the second dose of the vaccination.
aThe same serum panels described in Table 1 were used to determine the titers of neuraminidase inhibition (NAI) antibodies with an enzyme-linked lectin assay.
bTwo reassortant A(H6N9) viruses were used as N9 antigen sources. Whereas both viruses express the same H6 hemagglutinin antigen from A/turkey/Massachusetts/3740/1965 virus, N9 antigens were expressed from AH1 virus and GD17S virus, respectively.
cSeroconversion refers to a ≥4-fold titer rise of NAI antibodies after the second dose of the vaccination.
Neuraminidase-Inhibiting Antibodies Induced by Either MF59- or AS03-Adjuvanted A(H7N9) Candidate Vaccine Virus
| Adjuvant . | Serum Pairsa . | N9 Antigenb . | Pre-GMT (95% CI) . | Post-GMT (95% CI) . | Seroconversion, No. (%)c . |
|---|---|---|---|---|---|
| MF59 | n = 30 | H6N9 virus (AH1) | 6.5 (5.3–8.1) | 68.9 (49.6–95.7) | 25/30 (83.3) |
| H6N9 virus (GD17S) | 10.7 (7.2–15.9) | 228.9 (169.4–309.3) | 28/30 (93.33) | ||
| AS03 | n = 30 | H6N9 virus (AH1) | 9.0 (6.3–12.8) | 94.0 (64.1–138.1) | 25/30 (83.3) |
| H6N9 virus (GD17S) | 21.1 (11.9–37.9) | 254.0 (179.3–360.0) | 27 (90.00) |
| Adjuvant . | Serum Pairsa . | N9 Antigenb . | Pre-GMT (95% CI) . | Post-GMT (95% CI) . | Seroconversion, No. (%)c . |
|---|---|---|---|---|---|
| MF59 | n = 30 | H6N9 virus (AH1) | 6.5 (5.3–8.1) | 68.9 (49.6–95.7) | 25/30 (83.3) |
| H6N9 virus (GD17S) | 10.7 (7.2–15.9) | 228.9 (169.4–309.3) | 28/30 (93.33) | ||
| AS03 | n = 30 | H6N9 virus (AH1) | 9.0 (6.3–12.8) | 94.0 (64.1–138.1) | 25/30 (83.3) |
| H6N9 virus (GD17S) | 21.1 (11.9–37.9) | 254.0 (179.3–360.0) | 27 (90.00) |
Abbreviations: CI, confidence interval; GMT, geometric mean titer.
pre- day 0 of the vaccination. post- day 42–52 after the second dose of the vaccination.
aThe same serum panels described in Table 1 were used to determine the titers of neuraminidase inhibition (NAI) antibodies with an enzyme-linked lectin assay.
bTwo reassortant A(H6N9) viruses were used as N9 antigen sources. Whereas both viruses express the same H6 hemagglutinin antigen from A/turkey/Massachusetts/3740/1965 virus, N9 antigens were expressed from AH1 virus and GD17S virus, respectively.
cSeroconversion refers to a ≥4-fold titer rise of NAI antibodies after the second dose of the vaccination.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
